Topical nonsteroidal anti-inflammatory drugs for macular edema

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Russo, Andrea ^a   Costagliola, Ciro ^b   Delcassi, Luisa ^a   Parmeggiani, Francesco ^c   Romano, Mario R ^d   Dell'Omo, Roberto ^b   Semeraro, Francesco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFENAC; BEVACIZUMAB; BROMFENAC; CORTICOSTEROID; DICLOFENAC; FLUOROMETHOLONE; FLURBIPROFEN; INDOMETACIN; KETOROLAC; KETOROLAC TROMETAMOL; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PRANOPROFEN; PROSTAGLANDIN SYNTHASE; RANIBIZUMAB; VASCULOTROPIN; COMPLEMENT; PROSTAGLANDIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; CATARACT EXTRACTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG ADSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PENETRATION; HUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; AGING; ANIMAL; DISEASE COURSE; METABOLISM; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; TOPICAL DRUG ADMINISTRATION;

CYSTOIDEA;

ADMINISTRATION, TOPICAL; AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATARACT EXTRACTION; COMPLEMENT SYSTEM PROTEINS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RETINAL DISEASES;

EID: 84887336676     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/476525     Document Type: Review

References (129)

1. Schoenberger S. D., Kim S. J., Nonsteroidal anti-inflammatory drugs for retinal disease. International Journal of Inflammation 2013 2013 8 281981 10.1155/2013/281981
2. Flach A. J., Cyclo-oxygenase inhibitors in ophthalmology. Survey of Ophthalmology 1992 36 4 259 284 2-s2.0-0026515404 10.1016/0039-6257(92)90095-B
3. Flach A. J., Topical nonsteroidal antiinflammatory drugs in ophthalmology. International Ophthalmology Clinics 2002 42 1 1 11 2-s2.0-0036143229 (Pubitemid 34075973)
4. Flaxel C., Schain M. B., Hamon S. C., Francis P. J., Prospective randomized controlled trial of combination ranibizumab (lucentis) and bromfenac (xibrom) for neovascular age-related macular degeneration: a pilot study. Retina 2012 32 3 417 423 2-s2.0-84858069707 10.1097/IAE.0b013e318229b0af
5. Gomi F., Sawa M., Tsujikawa M., Nishida K., Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 2012 32 1804 1810
6. Filho J. P. S., Martins M. C., Correa Z. M. S., Odashiro A. N., Antecka E., Coutinho A. B., Macedo C. R., Vianna R. N. G., Burnier M. N. Jr., The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment. American Journal of Ophthalmology 2006 142 4 625 631 2-s2.0-33748985035 10.1016/j.ajo.2006.05.053 (Pubitemid 44442081)
7. Russo A., Costagliola C., Delcassi L., Romano M. R., Semeraro F., A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration. British Journal of Ophthalmology 2013 97 10 1273 1276 10.1136/bjophthalmol-2013-303417
8. Takahashi H., Yanagi Y., Tamaki Y., Uchida S., Muranaka K., COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochemical and Biophysical Research Communications 2004 325 2 461 466 2-s2.0-7644236908 10.1016/j.bbrc.2004.10.054 (Pubitemid 39458017)
9. Ahuja M., Dhake A. S., Sharma S. K., Majumdar D. K., Topical ocular delivery of NSAIDs. AAPS Journal 2008 10 2 229 241 2-s2.0-53849143939 10.1208/s12248-008-9024-9
10. Miyake K., Ibaraki N., Prostaglandins and cystoid macular edema. Survey of Ophthalmology 2002 47 supplement 1 S203 S218 2-s2.0-0036669682 10.1016/S0039-6257(02)00294-1 (Pubitemid 35232234)
11. Simmons D. L., Botting R. M., Hla T., Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 2004 56 3 387 437 2-s2.0-4143107932 10.1124/pr.56.3.3 (Pubitemid 39096597)
12. Davies N. M., Good R. L., Roupe K. A., Yáñez J. A., Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?-Not as easy as 1, 2, 3. Journal of Pharmacy & Pharmaceutical Sciences 2004 7 217 226 (Pubitemid 41528895)
13. Botting R. M., Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacological Reports 2010 62 3 518 525 2-s2.0-77954850148
14. Chin M. S., Nagineni C. N., Hooper L. C., Detrick B., Hooks J. J., Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Investigative Ophthalmology and Visual Science 2001 42 10 2338 2346 2-s2.0-0034848585 (Pubitemid 32848864)
15. Needleman P., Isakson P. C., The discovery and function of COX-2. Journal of Rheumatology 1997 24 49 6 8 2-s2.0-0030829359
16. Kim S. J., Flach A. J., Jampol L. M., Nonsteroidal anti-inflammatory drugs in ophthalmology. Survey of Ophthalmology 2010 55 2 108 133 2-s2.0-75949096248 10.1016/j.survophthal.2009.07.005
17. Kim S. J., Toma H. S., Barnett J. M., Penn J. S., Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Experimental Eye Research 2010 91 4 537 543 2-s2.0-79955954484 10.1016/j.exer.2010.07.011
18. Kim S. J., Toma H. S., Inhibition of choroidal neovascularization by intravitreal ketorolac. Archives of Ophthalmology 2010 128 5 596 600 2-s2.0-77952122491 10.1001/archophthalmol.2010.69
19. Maloney S. C., Fernandes B. F., Castiglione E., Antecka E., Martins C., Marshall J., Di Cesare S., Logan P., Burnier M. N. Jr., Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina 2009 29 2 176 180 2-s2.0-63249116911 10.1097/IAE.0b013e3181884fa6
20. Aiello L. P., Pierce E. A., Foley E. D., Takagi H., Chen H., Riddle L., Ferrara N., King G. L., Smith L. E. H., Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proceedings of the National Academy of Sciences of the United States of America 1995 92 23 10457 10461 2-s2.0-0028786651 10.1073/pnas.92.23.10457
21. Ayalasomayajula S. P., Kompella U. B., Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. European Journal of Pharmacology 2003 458 3 283 289 2-s2.0-0037419532 10.1016/S0014-2999(02)02793-0 (Pubitemid 36009467)
22. Johnson E. I. M., Dunlop M. E., Larkins R. G., Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Current Eye Research 1999 18 2 79 82 2-s2.0-0033023194 (Pubitemid 29137563)
23. Deutsch T. A., Hughes W. F., Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. American Journal of Ophthalmology 1979 87 4 536 540 2-s2.0-0018348176 (Pubitemid 9125613)
24. Monnier Y., Zaric J., Rüegg C., Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Current Drug Targets 2005 4 1 31 38 2-s2.0-17844404586 10.2174/1568010053622975 (Pubitemid 40584850)
25. Sawaoka H., Tsuji S., Tsujii M., Gunawan E. S., Sasaki Y., Kawano S., Hori M., Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Laboratory Investigation 1999 79 12 1469 1477 2-s2.0-0033391630 (Pubitemid 30013912)
26. Yamada M., Kawai M., Kawai Y., Mashima Y., The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Current Eye Research 1999 19 4 300 304 2-s2.0-0032719928
27. Joussen A. M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Döhmen S., Adamis A. P., Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. The FASEB Journal 2002 16 3 438 440 2-s2.0-0036517850
28. Kern T. S., Miller C. M., Du Y., Zheng L., Mohr S., Ball S. L., Kim M., Jamison J. A., Bingaman D. P., Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007 56 2 373 379 2-s2.0-33847028707 10.2337/db05-1621
29. Tasman W., Jaeger E. A., Duane's Foundations of Clinical Ophthalmology: Ocular Anatomy, Embryology and Teratology. Physiology of the Eye and Visual System. Pathology of the Eye 1991 Philadelphia, Pa, USA J.B. Lippincott
30. Schalnus R., Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003 217 2 89 98 2-s2.0-0037280734 10.1159/000068563 (Pubitemid 36237702)
31. Gupta M., Majumdar D. K., Effect of concentration, pH, and preservative on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous drops. Indian Journal of Experimental Biology 1997 35 8 844 849 2-s2.0-0030871003
32. Chen E., Benz M. S., Fish R. H., Brown D. M., Wong T. P., Kim R. Y., Major J. C., Use of nepafenac (Nevanac)in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clinical Ophthalmology 2010 4 1 1249 1252 2-s2.0-78650683541 10.2147/OPTH.S14092
33. Zweifel S. A., Engelbert M., Khan S., Freund K. B., Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009 29 10 1527 1531 2-s2.0-73349105630 10.1097/IAE.0b013e3181b32f4c
34. Ke T., Graff G., Spellman J. M., Yanni J. M., Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000 24 4 371 384 2-s2.0-0034041303 10.1023/A:1007001131987 (Pubitemid 30367883)
35. Walters T., Raizman M., Ernest P., Gayton J., Lehmann R., In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. Journal of Cataract and Refractive Surgery 2007 33 9 1539 1545 2-s2.0-34548142929 10.1016/j.jcrs.2007.05.015 (Pubitemid 47299180)
36. Gamache D. A., Graff G., Brady M. T., Spellman J. M., Yanni J. M., Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: i. Assessment of anti- inflammatory efficacy. Inflammation 2000 24 4 357 370 2-s2.0-0034045508 10.1023/A: 1007049015148 (Pubitemid 30367882)
37. Bucci F. A., Waterbury L. D., Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Advances in therapy 2011 28 12 1089 1095 2-s2.0-84860561911
38. Bucci F. A. Jr., Waterbury L. D., A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Current Medical Research and Opinion 2011 27 12 2235 2239 2-s2.0-81855221195 10.1185/03007995.2011.626018
39. Waterbury L. D., Silliman D., Jolas T., Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Current Medical Research and Opinion 2006 22 6 1133 1140 2-s2.0-33745685717 10.1185/030079906X112471 (Pubitemid 44000733)
40. Ellis P. P., Pfoff D. S., Bloedow D. C., Riegel M., Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. Journal of Ocular Pharmacology 1994 10 4 677 682 2-s2.0-0028609425
41. Bucci F. A. Jr., Waterbury L. D., Amico L. M., Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. American Journal of Ophthalmology 2007 144 1 146 147 2-s2.0-34250723434 10.1016/j.ajo.2007.02.034 (Pubitemid 46963171)
42. Heier J. S., Awh C. C., Busbee B. G., Waterbury L. D., Daniel P., Stoller G. L., Cleary T. S., Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina 2009 29 9 1310 1313 2-s2.0-70350161079 10.1097/IAE.0b013e3181b094e6
43. Quaranta L., Katsanos A., Russo A., Riva I., 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Survey of Ophthalmology 2013 58 26 41
44. Costagliola C., Parmeggiani F., Antinozzi P. P., Caccavale A., Cotticelli L., Sebastiani A., The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Experimental Eye Research 2005 81 5 610 615 2-s2.0-27444440877 10.1016/j.exer.2005.03.020 (Pubitemid 41532006)
45. Costagliola C., Campa C., Perri P., Parmeggiani F., Romano M. R., Incorvaia C., Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost. Current Eye Research 2008 33 5-6 477 482 2-s2.0-47349088375 10.1080/02713680802100845 (Pubitemid 351998849)
46. Flach A. J., Topical nonsteroidal antiinflammatory drugs in ophthalmology. International Ophthalmology Clinics 2002 42 1 1 11 2-s2.0-0036143229 (Pubitemid 34075973)
47. Gallenga P. E., Mastropasqua L., Lobefalo L., Della Loggia G., Ballone E., D'Annunzio G., Brancato R., Bandello F., Carones F., Sebastiani A., Capocotta A., Lamberti G., Ponte F., Cillino A., Morreale S., Neushuler R., Monaco C., Bucci M. G., Bonini S., Tognetto D., Lovisato A., Menchini U., Lanzetta P., Mansutti L., Bianco S., Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long-term cystoid macular edema. Journal of Cataract and Refractive Surgery 1997 23 8 1183 1189 2-s2.0-9844221954 (Pubitemid 27481699)
48. Blaydes J. E. Jr., Kelley E. P., Walt J. G., DeGryse R. E., Harper D. G., Novack G. D., Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. Journal of Cataract and Refractive Surgery 1993 19 4 481 487 2-s2.0-0027178712 (Pubitemid 23234130)
49. Donnenfeld E. D., Holland E. J., Stewart R. H., Gow J. A., Grillone L. R., Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007 114 9 1653 1662 2-s2.0-34548224212 10.1016/j.ophtha.2006.12.029 (Pubitemid 47332670)
50. Heier J., Cheetham J. K., DeGryse R., Dirks M. S., Caldwell D. R., Silverstone D. E., Rosenthal A., Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. American Journal of Ophthalmology 1999 127 3 253 259 2-s2.0-0004580463 10.1016/S0002-9394(98)00413-9 (Pubitemid 29128121)
51. Duong H. Q., Westfield K. C., Chalkley T. H. F., Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. Journal of Cataract and Refractive Surgery 2007 33 11 1925 1929 2-s2.0-35448967868 10.1016/j.jcrs.2007.07.017 (Pubitemid 47628809)
52. Hirneiss C., Neubauer A. S., Kampik A., Schönfeld C., Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction. A prospective, randomized, double-masked study. Graefe's Archive for Clinical and Experimental Ophthalmology 2005 243 8 768 773 2-s2.0-24944536363 10.1007/s00417-005-1126-9 (Pubitemid 41300417)
53. Kraff M. C., Martin R. G., Neumann A. C., Weinstein A. J., Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. Journal of Cataract and Refractive Surgery 1994 20 2 138 144 2-s2.0-0028288895 (Pubitemid 24100165)
54. Lane S. S., Modi S. S., Lehmann R. P., Holland E. J., Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. Journal of Cataract and Refractive Surgery 2007 33 1 53 58 2-s2.0-33845770182 10.1016/j.jcrs.2006.08.043 (Pubitemid 46001537)
55. Missotten L., Richard C., Trinquand C., Vrijghem J. C., Lamalle D., Zeyen T. H., Hennekes R., Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. Ophthalmologica 2001 215 1 43 50 2-s2.0-0035179154 10.1159/000050825 (Pubitemid 32011330)
56. Simone J. N., Pendelton R. A., Jenkins J. E., Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. Journal of Cataract and Refractive Surgery 1999 25 5 699 704 2-s2.0-0032900352 10.1016/S0886-3350(99)00023-1 (Pubitemid 29222602)
57. Solomon K. D., Cheetham J. K., DeGryse R., Brint S. F., Rosenthal A., Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001 108 2 331 337 2-s2.0-0035153649 10.1016/S0161-6420(00)00543-1 (Pubitemid 32115965)
58. Wittpenn J. R., Silverstein S., Heier J., Kenyon K. R., Hunkeler J. D., Earl M., A randomized, masked comparison of topical ketorolac 0. 4% plus steroid vs steroid alone in low-risk cataract surgery patients. American Journal of Ophthalmology 2008 146 4 554 560 2-s2.0-51649089809 10.1016/j.ajo.2008.04.036
59. Flach A. J., Kraff M. C., Sanders D. R., Tanenbaum L., The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier. Archives of Ophthalmology 1988 106 4 480 483 2-s2.0-0023950402
60. Heier J. S., Topping T. M., Baumann W., Dirks M. S., Chern S., Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000 107 11 2034 2039 2-s2.0-0033757470 10.1016/S0161-6420(00)00365-1
61. Kim S. J., Lo W. R., Hubbard G. B. III, Srivastava S. K., Denny J. P., Martin D. F., Yan J., Bergstrom C. S., Cribbs B. E., Schwent B. J., Aaberg T. M. Sr., Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Archives of Ophthalmology 2008 126 9 1203 1208 2-s2.0-51649106232 10.1001/archopht.126.9.1203
62. Loewenstein A., Zur D., Postsurgical cystoid macular edema. Developments in Ophthalmology 2010 47 148 159 2-s2.0-77956377239 10.1159/000320078
63. Flach A. J., The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society 1998 96 557 634 2-s2.0-0032412542 (Pubitemid 29012928)
64. Yilmaz T., Cordero-Coma M., Gallagher M. J., Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye 2012 26 2 252 258 2-s2.0-84856589292 10.1038/eye.2011.296
65. Ersoy L., Caramoy A., Ristau T., Kirchhof B., Fauser S., Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery. British Journal of Ophthalmology 2013 97 862 865
66. Kim S. J., Equi R., Bressler N. M., Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007 114 5 881 889 2-s2.0-34247401025 10.1016/j.ophtha.2006.08.053 (Pubitemid 46635831)
67. Lobo C. L., Faria P. M., Soares M. A., Bernardes R. C., Cunha-Vaz J. G., Macular alterations after small-incision cataract surgery. Journal of Cataract and Refractive Surgery 2004 30 4 752 760 2-s2.0-16544366754 10.1016/S0886- 3350(03)00582-0 (Pubitemid 38501467)
68. Ursell P. G., Spalton D. J., Whitcup S. M., Nussenblatt R. B., Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. Journal of Cataract and Refractive Surgery 1999 25 11 1492 1497 2-s2.0-0032693316 10.1016/S0886-3350(99)00196-0 (Pubitemid 29523175)
69. Rossetti L., Chaudhuri J., Dickersin K., Medical prophylaxis and treatment of cystoid macular edema after cataract surgery: the results of a meta-analysis. Ophthalmology 1998 105 3 397 405 2-s2.0-0031916502 10.1016/S0161-6420(98)93018-4 (Pubitemid 28125090)
70. Miyake K., Sakamura S., Miura H., Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. British Journal of Ophthalmology 1980 64 5 324 328 2-s2.0-0018972051 (Pubitemid 10046426)
71. Yannuzzi L. A., Landau A. N., Turtz A. I., Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology 1981 88 9 947 954 2-s2.0-0019416322 (Pubitemid 11060920)
72. Kraff M. C., Sanders D. R., Jampol L. M., Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology 1982 89 8 885 890 2-s2.0-0019950142 (Pubitemid 12019471)
73. Flach A. J., Stegman R. C., Graham J., Kruger L. P., Prophylaxis of aphakic cystoid macular edema without corticosteroids: a paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990 97 10 1253 1258 2-s2.0-0025047843 (Pubitemid 20353967)
74. Solomon L. D., Boyaner D., Breslin C. W., Demco T. A., LeBlanc R., Lemire J., Mintsioulis G., Ober M., Ramsey M., Sutton H. F., Taylor G., Grant S., Jarus G., Cheetham J. K., Barnett P. S., DeGryse R., Aswad A., Gwon A., Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery 1995 21 1 73 81 2-s2.0-0028945083
75. Miyake K., Masuda K., Shirato S., Oshika T., Eguchi K., Hoshi H., Majima Y., Kimura W., Hayashi F., Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Japanese Journal of Ophthalmology 2000 44 1 58 67 2-s2.0-0033973488 10.1016/S0021-5155(99)00176-8 (Pubitemid 30029136)
76. Kim S. J., Bressler N. M., Optical coherence tomography and cataract surgery. Current Opinion in Ophthalmology 2009 20 1 46 51 2-s2.0-58149264987 10.1097/ICU.0b013e3283199162
77. Yannuzzi L. A., Klein R. M., Wallyn R. H., Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology 1977 84 4 517 519 2-s2.0-0017763105 (Pubitemid 8221644)
78. Burnett J., Tessler H., Isenberg S., Tso M. O. M., Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery 1983 14 2 150 152 2-s2.0-0020581791 (Pubitemid 13124519)
79. Flach A. J., Dolan B. J., Irvine A. R., Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology 1987 103 4 479 486 2-s2.0-0023142793 (Pubitemid 17056889)
80. Flach A. J., Jampol L. M., Weinberg D., Kraff M. C., Yannuzzi L. A., Campo R. V., Neumann A. C., Cupples H. P., Lefler W. H., Pulido J. S., Lavelle C., Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology 1991 112 5 514 519 2-s2.0-0025946584
81. Sivaprasad S., Bunce C., Crosby-Nwaobi R., Sivaprasad S., Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. The Cochrane Collaboration 2012 Chichester, UK John Wiley & Sons Cochrane Database of Systematic Reviews
82. Almeida D. R. P., Khan Z., Xing L., Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract & Refractive Surgery 2012 38 1537 1543
83. Warren K. A., Bahrani H., Fox J. E., NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010 30 2 260 266 2-s2.0-76749101160 10.1097/IAE.0b013e3181b8628e
84. Hariprasad S. M., Akduman L., Clever J. A., Ober M., Recchia F. M., Mieler W. F., Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clinical Ophthalmology 2009 3 1 147 154 2-s2.0-77949575051
85. Klein R., Peto T., Bird A., Vannewkirk M. R., The epidemiology of age-related macular degeneration. American Journal of Ophthalmology 2004 137 3 486 495 2-s2.0-1542297335 10.1016/j.ajo.2003.11.069 (Pubitemid 38328641)
86. D'Amico D. J., Diseases of the retina. The New England Journal of Medicine 1994 331 95 106 (Pubitemid 24984702)
87. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
88. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655 (Pubitemid 44511558)
89. Zarbin M. A., Current concepts in the pathogenesis of age-related macular degeneration. Archives of Ophthalmology 2004 122 4 598 614 2-s2.0-1842478123 10.1001/archopht.122.4.598 (Pubitemid 38456297)
90. Edwards A. O., Ritter R. III, Abel K. J., Manning A., Panhuysen C., Farrer L. A., Complement factor H polymorphism and age-related macular degeneration. Science 2005 308 5720 421 424 2-s2.0-17244379811 10.1126/science.1110189 (Pubitemid 40530082)
91. Haines J. L., Hauser M. A., Schmidt S., Scott W. K., Olson L. M., Gallins P., Spencer K. L., Shu Y. K., Noureddine M., Gilbert J. R., Schnetz-Boutaud N., Agarwal A., Postel E. A., Pericak-Vance M. A., Complement factor H variant increases the risk of age-related macular degeneration. Science 2005 308 5720 419 421 2-s2.0-20244388812 10.1126/science.1110359 (Pubitemid 40530081)
92. Klein R. J., Zeiss C., Chew E. Y., Tsai J., Sackler R. S., Haynes C., Henning A. K., SanGiovanni J. P., Mane S. M., Mayne S. T., Bracken M. B., Ferris F. L., Ott J., Barnstable C., Hoh J., Complement factor H polymorphism in age-related macular degeneration. Science 2005 308 5720 385 389 2-s2.0-20244380171 10.1126/science.1109557 (Pubitemid 40530070)
93. 402H polymorphisms and age-related macular degeneration. Human Molecular Genetics 2006 15 18 2784 2790 2-s2.0-33748752137 10.1093/hmg/ddl220 (Pubitemid 44400405)
94. Parmeggiani F., Romano M. R., Costagliola C., Mechanism of inflammation in age-related macular degeneration. Mediators of Inflammation 2012 2012 16 546786 10.1155/2012/546786
95. Bora P. S., Sohn J., Cruz J. M. C., Jha P., Nishihori H., Wang Y., Kaliappan S., Kaplan H. J., Bora N. S., Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. Journal of Immunology 2005 174 1 491 497 2-s2.0-10844231850 (Pubitemid 40007439)
96. Patel M., Chan C., Immunopathological aspects of age-related macular degeneration. Seminars in Immunopathology 2008 30 2 97 110 2-s2.0-42449105692 10.1007/s00281-008-0112-9
97. Wang Y., Wang V. M., Chan C.-C., The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye 2011 25 2 127 139 2-s2.0-79951561948 10.1038/eye.2010.196
98. Penfold P. L., Provis J. M., Furby J. H., Gatenby P. A., Billson F. A., Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 1990 228 270 274 (Pubitemid 20150313)
99. Gu X., Meer S. G., Miyagi M., Rayborn M. E., Hollyfield J. G., Crabb J. W., Salomon R. G., Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. The Journal of Biological Chemistry 2003 278 43 42027 42035 2-s2.0-0142242222 10.1074/jbc.M305460200 (Pubitemid 37310467)
100. Morohoshi K., Goodwin A. M., Ohbayashi M., Ono S. J., Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. Journal of Autoimmunity 2009 33 3-4 247 254 2-s2.0-71649108317 10.1016/j.jaut.2009.09.003
101. in 't Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., Breteler M. M. B., Stricker B. H. C., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. The New England Journal of Medicine 2001 345 21 1515 1521 2-s2.0-0035936004 10.1056/NEJMoa010178 (Pubitemid 33144916)
102. Stewart W. F., Kawas C., Corrada M., Metter E. J., Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997 48 3 626 632 2-s2.0-0030897133 (Pubitemid 27120096)
103. McGeer P. L., Sibley J., Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiology of Aging 2005 26 8 1199 1203 2-s2.0-19444361805 10.1016/j.neurobiolaging.2005.02.003 (Pubitemid 40726013)
104. Wilson H. L., Schwartz D. M., Bhatt H. R. F., McCulloch C. E., Duncan J. L., Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. American Journal of Ophthalmology 2004 137 4 615 624 2-s2.0-1842451938 10.1016/j.ajo.2003.10.025 (Pubitemid 38446673)
105. Suzuki M., Suzuki T., Nagano A., Hirasawa M., Sakuyama K., Mizuki N., Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration. European Journal of Ophthalmology 2012 22 495 498
106. Liew G., Mitchell P., Wong T. Y., Rochtchina E., Wang J. J., The association of aspirin use with age-related macular degeneration. JAMA Internal Medicine 2013 173 258 264
107. de Jong P. T. V. M., Chakravarthy U., Rahu M., Seland J., Soubrane G., Topouzis F., Vingerling J. R., Vioque J., Young I., Fletcher A. E., Associations between aspirin use and aging macula disorder: the European eye study. Ophthalmology 2012 119 1 112 118 2-s2.0-84855299970 10.1016/j.ophtha.2011.06.025
108. Du Y., Sarthy V. P., Kern T. S., Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2004 287 4 R735 R741 2-s2.0-4644243657 10.1152/ajpregu.00080.2003 (Pubitemid 39280457)
109. Yanni S. E., McCollum G. W., Penn J. S., Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells. Experimental Eye Research 2010 91 1 34 41 2-s2.0-77953361126 10.1016/j.exer.2010.03.019
110. Antonetti D. A., Klein R., Gardner T. W., Diabetic retinopathy. The New England Journal of Medicine 2012 366 13 1227 1239 2-s2.0-84859012407 10.1056/NEJMra1005073
111. Knudsen S. T., Bek T., Poulsen P. L., Hove M. N., Rehling M., Mogensen C. E., Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. Diabetes Care 2002 25 12 2328 2334 2-s2.0-0038153414
112. Funatsu H., Yamashita H., Ikeda T., Nakanishi Y., Kitano S., Hori S., Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. American Journal of Ophthalmology 2002 133 4 537 543 2-s2.0-0036207489 10.1016/S0002-9394(02)01323-5 (Pubitemid 34258063)
113. Adamis A. P., Berman A. J., Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in Immunopathology 2008 30 2 65 84 2-s2.0-42449135678 10.1007/s00281-008-0111-x
114. Sue Lane L., Jansen P. D., Lahav M., Rudy C., Circulating prostacyclin and thromboxane levels in patients with diabetic retinopathy. Ophthalmology 1982 89 7 763 766 2-s2.0-0019948473 (Pubitemid 12039441)
115. Zhou J., Wang S., Xia X., Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Current Eye Research 2012 37 5 416 420 2-s2.0-84859891447 10.3109/02713683.2012.661114
116. Schoenberger S. D., Kim S. J., Sheng J., Rezaei K. A., Lalezary M., Cherney E., Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Investigative Ophthalmology & Visual Science 2012 53 5906 5911
117. Bressler S. B., Qin H., Melia M., Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology 2013 131 8 1033 1040
118. Yanni S. E., Barnett J. M., Clark M. L., Penn J. S., The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Investigative Ophthalmology and Visual Science 2009 50 11 5479 5486 2-s2.0-77953359022 10.1167/iovs.09-3652
119. Kern T. S., Engerman R. L., Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001 50 7 1636 1642 2-s2.0-0035409354 (Pubitemid 33639605)
120. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991 98 757 765
121. Powell E. U., Field R., Diabetic retinopathy and rheumatoid arthritis. The Lancet 1964 284 7349 17 18 2-s2.0-50549220514
122. Baudoin C., Passa P., Sharp P., Kohner E., Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989 38 4 491 498 2-s2.0-0024500488 (Pubitemid 19105409)
123. Hattori Y., Hashizume K., Nakajima K., Nishimura Y., Naka M., Miyanaga K., The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Current Medical Research and Opinion 2007 23 8 1913 1917 2-s2.0-34548133077 10.1185/030079907X218770 (Pubitemid 47300390)
124. Chew E. Y., Kim J., Coleman H. R., Aiello L. P., Fish G., Ip M., Haller J. A., Figueroa M., Martin D., Callanan D., Avery R., Hammel K., Thompson D. J. S., Ferris F. L., Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina 2010 30 3 459 467 2-s2.0-77949393585 10.1097/IAE.0b013e3181bcf1a0
125. Callanan D., Williams P., Topical nepafenac in the treatment of diabetic macular edema. Clinical Ophthalmology 2008 2 689 692
126. Soheilian M., Karimi S., Ramezani A., Peyman G. A., Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010 30 3 509 515 2-s2.0-77949349000 10.1097/IAE. 0b013e3181bdfa43
127. do Ceu Afonso Reis A., Vianna R. N. G., dos Reis R. S. M., Cardoso G. P., Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation. Arquivos Brasileiros de Oftalmologia 2010 73 4 338 342 2-s2.0-78449238708 10.1590/S0004- 27492010000400007
128. Maldonado R. M., Vianna R. N. G., Cardoso G. P., de Magalhães A. V., Burnier M. N. Jr., Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Current Eye Research 2011 36 8 768 773 2-s2.0-79960709309 10.3109/02713683.2011.585734
129. Elbendary A. M., Shahin M. M., Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular EDEMA.